Standard BioTools Inc.
LAB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.10 | 0.04 | -0.00 | -0.93 |
| FCF Yield | -24.56% | -26.36% | -101.72% | -19.30% |
| EV / EBITDA | -4.10 | -4.07 | -0.65 | -8.69 |
| Quality | ||||
| ROIC | -31.48% | -27.76% | -32.47% | -26.65% |
| Gross Margin | 48.31% | 47.44% | 37.83% | 53.13% |
| Cash Conversion Ratio | 1.03 | 0.58 | 0.47 | 0.74 |
| Growth | ||||
| Revenue 3-Year CAGR | 21.21% | -6.62% | -10.83% | 3.66% |
| Free Cash Flow Growth | -229.18% | 50.51% | -62.57% | -103.76% |
| Safety | ||||
| Net Debt / EBITDA | 1.13 | -0.85 | -0.12 | -1.90 |
| Interest Coverage | -52.85 | -16.77 | -26.83 | -17.65 |
| Efficiency | ||||
| Inventory Turnover | 2.21 | 2.72 | 2.84 | 2.94 |
| Cash Conversion Cycle | 185.51 | 141.26 | 145.66 | 112.17 |